The FDA approves Celgene's (CELG) Pomalyst brand therapy for patients with multiple myeloma. The...

|About: Celgene Corporation (CELG)|By:, SA News Editor

The FDA approves Celgene's (CELG) Pomalyst brand therapy for patients with multiple myeloma. The approval is based on response rate; as of yet, clinical benefit, such as improvement in survival or symptoms, has not been verified.